Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA
Cannabix is developing alcohol and marijuana breathalyzer devices to give law enforcement and employers a tool to enhance public safetyVANCOUVER,...
Month: July 2024
Parexel Releases 2023 Environmental, Social and Governance Report
DURHAM, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the...
Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
Veru to Participate in the BTIG Virtual Biotechnology Conference
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index
Beauty Pioneer Kendra Bracken-Ferguson Appointed CEO of Carmell Corporation To Champion a Technological Revolution in Regenerative Skincare and Haircare and Build Beauty...
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis...
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary...
Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA
Richland WA, July 29, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Provides IDE Submission Status Update The...
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX:...
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go...
iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite ExpansionNASHUA, N.H. and WILLIAMSVILLE, N.Y. and RALEIGH, N.C.,...
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next...
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
Research Published in THE LANCET's eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE,...
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory...
Hummingbird Bioscience Announces Key Leadership Appointments
Kon Yew Kwek, BM BCh, DPhil, appointed Chief Medical Officer Lisa Ooi, PhD, appointed Chief Operating Officer SAN FRANCISCO and...
Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank
SEATTLE and VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
The Phase 2 trial of VTX958 in Crohn’s disease did not meet its primary endpoint of change from baseline in...
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was...
Assure Announces Further Extension of Exchange Offer Relating to its Convertible Notes
DENVER, July 29, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (“Assure” or the “Company”) (NASDAQ: IONM), today announced that it has...
PDS Biotech to Participate at BTIG Virtual Biotechnology Conference
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...